Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`
`Input Field
`
`SERIAL NUMBER
`
`LAW OFFICE ASSIGNED
`
`MARK SECTION
`
`MARK FILE NAME
`
`LITERAL ELEMENT
`
`STANDARD CHARACTERS
`
`USPTO-GENERATED IMAGE
`
`COLOR(S) CLAIMED
`(If applicable)
`
`DESCRIPTION OF THE MARK
`(and Color Location, if applicable)
`
`The table below presents the data as entered.
`
`Entered
`
`87348251
`
`LAW OFFICE 118
`
`https://tmng-al.uspto.gov/resting2/api/img/87348251/large
`
`ATHENEX
`
`NO
`
`NO
`
`Color is not claimed as a feature of the mark.
`
`The mark consists of the word "ATHENEX", with a stylized "A" wherein the
`crossing line of the letter "A" is a curved line that is extended under the entire mark.
`The letter "X" has a curve in the opposing direction.
`
`GOODS AND/OR SERVICES SECTION (current)
`
`INTERNATIONAL CLASS
`
`DESCRIPTION
`
`005
`
`Prescription pharmaceutical products for a variety of diseases
`
`FILING BASIS
`
` FIRST USE ANYWHERE DATE
`
` FIRST USE IN COMMERCE DATE
`
`Section 1(a)
`
`At least as early as 11/02/2015
`
`At least as early as 02/08/2017
`
`GOODS AND/OR SERVICES SECTION (proposed)
`
`INTERNATIONAL CLASS
`
`TRACKED TEXT DESCRIPTION
`
`005
`
`Prescription pharmaceutical products for a variety of diseases; House mark for pharmaceuticals directed to treatment of diseases and disorders
`affecting the circulatory system, digestive system, excretory system, endocrine system, integumentary system/exocrine system, immune
`system and lymphatic system, muscular system, nervous system, renal system and urinary system, reproductive system, respiratory system,
`skeletal system, impacting the blood, brain, heart, lungs, kidneys, stomach, liver, pancreas, mammary glands, ovaries, uterus, testes, bladder,
`rectum, large intestine, small intestine, gall bladder, hair, skin, nails, muscles, bones, joints, tendons, spine, thymus, thyroid, lymph nodes,
`spleen, eyes, nose, trachea, esophagus, including anti-infectives, anti-emetics, narcotics/analgesics, pharmaceutical preparations for the
`treatment of infectious diseases, pharmaceutical preparations for the treatment of dermatological conditions, pharmaceutical products for the
`treatment of cancer, anesthesia and sedatives, pain relief, antiinflamatory preparations, antiepileptic agents, muscle relaxants
`
`FINAL DESCRIPTION
`
`House mark for pharmaceuticals directed to treatment of diseases and disorders affecting the circulatory system, digestive system, excretory
`system, endocrine system, integumentary system/exocrine system, immune system and lymphatic system, muscular system, nervous system,
`renal system and urinary system, reproductive system, respiratory system, skeletal system, impacting the blood, brain, heart, lungs, kidneys,
`stomach, liver, pancreas, mammary glands, ovaries, uterus, testes, bladder, rectum, large intestine, small intestine, gall bladder, hair, skin,
`nails, muscles, bones, joints, tendons, spine, thymus, thyroid, lymph nodes, spleen, eyes, nose, trachea, esophagus, including anti-infectives,
`anti-emetics, narcotics/analgesics, pharmaceutical preparations for the treatment of infectious diseases, pharmaceutical preparations for the
`
`
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`
`Input Field
`
`SERIAL NUMBER
`
`LAW OFFICE ASSIGNED
`
`MARK SECTION
`
`MARK FILE NAME
`
`LITERAL ELEMENT
`
`STANDARD CHARACTERS
`
`USPTO-GENERATED IMAGE
`
`COLOR(S) CLAIMED
`(If applicable)
`
`DESCRIPTION OF THE MARK
`(and Color Location, if applicable)
`
`The table below presents the data as entered.
`
`Entered
`
`87348251
`
`LAW OFFICE 118
`
`https://tmng-al.uspto.gov/resting2/api/img/87348251/large
`
`ATHENEX
`
`NO
`
`NO
`
`Color is not claimed as a feature of the mark.
`
`The mark consists of the word "ATHENEX", with a stylized "A" wherein the
`crossing line of the letter "A" is a curved line that is extended under the entire mark.
`The letter "X" has a curve in the opposing direction.
`
`GOODS AND/OR SERVICES SECTION (current)
`
`INTERNATIONAL CLASS
`
`DESCRIPTION
`
`005
`
`Prescription pharmaceutical products for a variety of diseases
`
`FILING BASIS
`
` FIRST USE ANYWHERE DATE
`
` FIRST USE IN COMMERCE DATE
`
`Section 1(a)
`
`At least as early as 11/02/2015
`
`At least as early as 02/08/2017
`
`GOODS AND/OR SERVICES SECTION (proposed)
`
`INTERNATIONAL CLASS
`
`TRACKED TEXT DESCRIPTION
`
`005
`
`Prescription pharmaceutical products for a variety of diseases; House mark for pharmaceuticals directed to treatment of diseases and disorders
`affecting the circulatory system, digestive system, excretory system, endocrine system, integumentary system/exocrine system, immune
`system and lymphatic system, muscular system, nervous system, renal system and urinary system, reproductive system, respiratory system,
`skeletal system, impacting the blood, brain, heart, lungs, kidneys, stomach, liver, pancreas, mammary glands, ovaries, uterus, testes, bladder,
`rectum, large intestine, small intestine, gall bladder, hair, skin, nails, muscles, bones, joints, tendons, spine, thymus, thyroid, lymph nodes,
`spleen, eyes, nose, trachea, esophagus, including anti-infectives, anti-emetics, narcotics/analgesics, pharmaceutical preparations for the
`treatment of infectious diseases, pharmaceutical preparations for the treatment of dermatological conditions, pharmaceutical products for the
`treatment of cancer, anesthesia and sedatives, pain relief, antiinflamatory preparations, antiepileptic agents, muscle relaxants
`
`FINAL DESCRIPTION
`
`House mark for pharmaceuticals directed to treatment of diseases and disorders affecting the circulatory system, digestive system, excretory
`system, endocrine system, integumentary system/exocrine system, immune system and lymphatic system, muscular system, nervous system,
`renal system and urinary system, reproductive system, respiratory system, skeletal system, impacting the blood, brain, heart, lungs, kidneys,
`stomach, liver, pancreas, mammary glands, ovaries, uterus, testes, bladder, rectum, large intestine, small intestine, gall bladder, hair, skin,
`nails, muscles, bones, joints, tendons, spine, thymus, thyroid, lymph nodes, spleen, eyes, nose, trachea, esophagus, including anti-infectives,
`anti-emetics, narcotics/analgesics, pharmaceutical preparations for the treatment of infectious diseases, pharmaceutical preparations for the
`
`
`
`treatment of dermatological conditions, pharmaceutical products for the treatment of cancer, anesthesia and sedatives, pain relief,
`antiinflamatory preparations, antiepileptic agents, muscle relaxants
`
`FILING BASIS
`
` FIRST USE ANYWHERE DATE
`
` FIRST USE IN COMMERCE DATE
`
`ADDITIONAL STATEMENTS SECTION
`
`Section 1(a)
`
`At least as early as 11/02/2015
`
`At least as early as 02/08/2017
`
`MISCELLANEOUS STATEMENT
`
` MISCELLANEOUS FILE NAME(S)
`
` ORIGINAL PDF FILE
`
` CONVERTED PDF FILE(S)
` (86 pages)
`
`The following is in response to the Office Action issued June 14, 2019. In
`accordance with the Trademark Examining Attorney's requirements, Applicant has
`attached as Exhibit A catalog and insert pages that support its use of its ATHENEX
`LOGO mark as a house mark. It is respectfully requested that the application
`proceed to publication.
`
`mis-3898219243-20191212144107485440_._EXHIBIT_A_-.pdf
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0002.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0003.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0004.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0005.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0006.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0007.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0008.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0009.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0010.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0011.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0012.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0013.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0014.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0015.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0016.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0017.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0018.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0019.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0020.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0021.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0022.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0023.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0024.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0025.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0026.JPG
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0027 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0028 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0029 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0030.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR003 1 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0032 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR003 3 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0034.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0035 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0036.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0037 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR003 8 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0039 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0040.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR004 1 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0042 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0043 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0044.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0045 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0046.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0047 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0048 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0049 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0050.JPG
`
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR005 1 .JPG
`
`
`
`
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0052 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR005 3 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0054.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0055 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0056.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0057 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR005 8 .JPG
`
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0059 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0060.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR006 1 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0062 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\8734825 1\Xm11 1\RFR0063 .JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0027.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0028.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0029.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0030.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0031.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0032.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0033.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0034.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0035.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0036.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0037.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0038.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0039.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0040.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0041.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0042.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0043.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0044.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0045.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0046.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0047.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0048.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0049.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0050.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0051.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0052.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0053.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0054.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0055.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0056.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0057.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0058.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0059.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0060.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0061.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0062.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0063.JPG
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0064.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0065.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0066.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0067.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0068.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0069.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0070.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0071.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0072.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0073.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0074.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0075.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0076.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0077.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0078.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0079.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0080.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0081.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0082.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0083.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0084.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0085.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0086.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348251\xml11\RFR0087.JPG
`
`ATTORNEY SECTION (current)
`
`NAME
`
`ATTORNEY BAR MEMBERSHIP NUMBER
`
`YEAR OF ADMISSION
`
`U.S. STATE/ COMMONWEALTH/ TERRITORY
`
`FIRM NAME
`
`INTERNAL ADDRESS
`
`STREET
`
`CITY
`
`STATE
`
`POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`Jacqueline M. Lesser
`
`NOT SPECIFIED
`
`NOT SPECIFIED
`
`NOT SPECIFIED
`
`BAKER & HOSTETLER LLP
`
`CIRA CENTRE, 12TH FLOOR
`
`2929 ARCH STREET
`
`PHILADELPHIA
`
`Pennsylvania
`
`19104-2891
`
`US
`
`215.568.3100
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`FAX
`
`
`215.568.3439
`
`BHIPDocket@bakerlaw.com
`
`AUTHORIZED TO COMMUNICATE VIA EMAIL
`
`Yes
`
`DOCKET/REFERENCE NUMBER
`
`099927.00038
`
`ATTORNEY SECTION (proposed)
`
`NAME
`
`Jacqueline M. Lesser
`
`ATTORNEY BAR MEMBERSHIP NUMBER
`
`YEAR OF ADMISSION
`
`U.S. STATE/ COMMONWEALTH/ TERRITORY
`
`XXX
`
`XXXX
`
`XX
`
`FIRM NAME
`
`INTERNAL ADDRESS
`
`STREET
`
`CITY
`
`STATE
`
`POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`
`BAKER & HOSTETLER LLP
`
`CIRA CENTRE, 12TH FLOOR
`
`2929 ARCH STREET
`
`PHILADELPHIA
`
`Pennsylvania
`
`19104-2891
`
`United States
`
`215.568.3100
`
`215.568.3439
`
`BHIPDocket@bakerlaw.com
`
`AUTHORIZED TO COMMUNICATE VIA EMAIL
`
`Yes
`
`DOCKET/REFERENCE NUMBER
`
`099927.00038
`
`OTHER APPOINTED ATTORNEY
`
`CORRESPONDENCE SECTION (current)
`
`Nancy Rubner Frandsen, Kevin M. Bovard, Lesley M. Grossberg, Lisa Bollinger
`Gehman, and Savannah Merceus
`
`NAME
`
`FIRM NAME
`
`INTERNAL ADDRESS
`
`STREET
`
`CITY
`
`STATE
`
`POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`
`JACQUELINE M. LESSER
`
`BAKER & HOSTETLER LLP
`
`CIRA CENTRE, 12TH FLOOR
`
`2929 ARCH STREET
`
`PHILADELPHIA
`
`Pennsylvania
`
`19104-2891
`
`US
`
`215.568.3100
`
`215.568.3439
`
`BHIPDocket@bakerlaw.com; jlesser@bakerlaw.com; jmbarr@bakerlaw.com
`
`AUTHORIZED TO COMMUNICATE VIA EMAIL
`
`Yes
`
`DOCKET/REFERENCE NUMBER
`
`099927.00038
`
`CORRESPONDENCE SECTION (proposed)
`
`
`
`NAME
`
`FIRM NAME
`
`INTERNAL ADDRESS
`
`STREET
`
`CITY
`
`STATE
`
`POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`
`Jacqueline M. Lesser
`
`BAKER & HOSTETLER LLP
`
`CIRA CENTRE, 12TH FLOOR
`
`2929 ARCH STREET
`
`PHILADELPHIA
`
`Pennsylvania
`
`19104-2891
`
`United States
`
`215.568.3100
`
`215.568.3439
`
`BHIPDocket@bakerlaw.com; jlesser@bakelaw.com; jmbarr@bakerlaw.com
`
`AUTHORIZED TO COMMUNICATE VIA EMAIL
`
`Yes
`
`DOCKET/REFERENCE NUMBER
`
`SIGNATURE SECTION
`
`RESPONSE SIGNATURE
`
`SIGNATORY'S NAME
`
`SIGNATORY'S POSITION
`
`SIGNATORY'S PHONE NUMBER
`
`DATE SIGNED
`
`AUTHORIZED SIGNATORY
`
`CONCURRENT APPEAL NOTICE FILED
`
`FILING INFORMATION SECTION
`
`SUBMIT DATE
`
`TEAS STAMP
`
`099927.00038
`
`/Jacqueline M. Lesser/
`
`Jacqueline M. Lesser
`
`Attorney of record, PA bar member
`
`215.564.2155
`
`12/13/2019
`
`YES
`
`NO
`
`Fri Dec 13 15:07:47 EST 2019
`
`USPTO/RFR-XX.XX.XXX.XXX-2
`0191213150747811173-87348
`251-70045e6d2a792d9fd2998
`5412dc50cc5f03c3f10191820
`ae3b2571113b63cc1-N/A-N/A
`-20191212144107485440
`
`Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`To the Commissioner for Trademarks:
`
`Application serial no. 87348251 ATHENEX (Stylized and/or with Design, see https://tmng-al.uspto.gov/resting2/api/img/87348251/large) has
`been amended as follows:
`
`CLASSIFICATION AND LISTING OF GOODS/SERVICES
`
`Applicant proposes to amend the following class of goods/services in the application:
`
`
`
`Current: Class 005 for Prescription pharmaceutical products for a variety of diseases
`Original Filing Basis:
`Filing Basis: Section 1(a), Use in Commerce: The applicant is using the mark in commerce, or the applicant's related company or licensee is
`using the mark in commerce, on or in connection with the identified goods and/or services. 15 U.S.C. Section 1051(a), as amended. The mark
`was first used at least as early as 11/02/2015 and first used in commerce at least as early as 02/08/2017 , and is now in use in such commerce.
`
`Proposed:
`Tracked Text Description: Prescription pharmaceutical products for a variety of diseases; House mark for pharmaceuticals directed to treatment
`of diseases and disorders affecting the circulatory system, digestive system, excretory system, endocrine system, integumentary system/exocrine
`system, immune system and lymphatic system, muscular system, nervous system, renal system and urinary system, reproductive system,
`respiratory system, skeletal system, impacting the blood, brain, heart, lungs, kidneys, stomach, liver, pancreas, mammary glands, ovaries, uterus,
`testes, bladder, rectum, large intestine, small intestine, gall bladder, hair, skin, nails, muscles, bones, joints, tendons, spine, thymus, thyroid,
`lymph nodes, spleen, eyes, nose, trachea, esophagus, including anti-infectives, anti-emetics, narcotics/analgesics, pharmaceutical preparations for
`the treatment of infectious diseases, pharmaceutical preparations for the treatment of dermatological conditions, pharmaceutical products for the
`treatment of cancer, anesthesia and sedatives, pain relief, antiinflamatory preparations, antiepileptic agents, muscle relaxants
`
`Class 005 for House mark for pharmaceuticals directed to treatment of diseases and disorders affecting the circulatory system, digestive system,
`excretory system, endocrine system, integumentary system/exocrine system, immune system and lymphatic system, muscular system, nervous
`system, renal system and urinary system, reproductive system, respiratory system, skeletal system, impacting the blood, brain, heart, lungs,
`kidneys, stomach, liver, pancreas, mammary glands, ovaries, uterus, testes, bladder, rectum, large intestine, small intestine, gall bladder, hair,
`skin, nails, muscles, bones, joints, tendons, spine, thymus, thyroid, lymph nodes, spleen, eyes, nose, trachea, esophagus, including anti-infectives,
`anti-emetics, narcotics/analgesics, pharmaceutical preparations for the treatment of infectious diseases, pharmaceutical preparations for the
`treatment of dermatological conditions, pharmaceutical products for the treatment of cancer, anesthesia and sedatives, pain relief, antiinflamatory
`preparations, antiepileptic agents, muscle relaxants
`Filing Basis: Section 1(a), Use in Commerce: The applicant is using the mark in commerce, or the applicant's related company or licensee is
`using the mark in commerce, on or in connection with the identified goods and/or services. 15 U.S.C. Section 1051(a), as amended. The mark
`was first used at least as early as 11/02/2015 and first used in commerce at least as early as 02/08/2017 , and is now in use in such commerce.
`The applicant's current attorney information: Jacqueline M. Lesser. Jacqueline M. Lesser of BAKER & HOSTETLER LLP, is located at
`
` CIRA CENTRE, 12TH FLOOR
` 2929 ARCH STREET
` PHILADELPHIA, Pennsylvania 19104-2891
` US
`The docket/reference number is 099927.00038.
`
`The phone number is 215.568.3100.
`
`The fax number is 215.568.3439.
`
`The email address is BHIPDocket@bakerlaw.com
`
`The applicants proposed attorney information: Jacqueline M. Lesser. Other appointed attorneys are Nancy Rubner Frandsen, Kevin M. Bovard,
`Lesley M. Grossberg, Lisa Bollinger Gehman, and Savannah Merceus. Jacqueline M. Lesser of BAKER & HOSTETLER LLP, is a member of
`the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
`
` CIRA CENTRE, 12TH FLOOR
` 2929 ARCH STREET
` PHILADELPHIA, Pennsylvania 19104-2891
` United States
`The docket/reference number is 099927.00038.
`
`The phone number is 215.568.3100.
`
`The fax number is 215.568.3439.
`
`The email address is BHIPDocket@bakerlaw.com
`
`Jacqueline M. Lesser submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest
`court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.
`
`
`
`The applicant's current correspondence information: JACQUELINE M. LESSER. JACQUELINE M. LESSER of BAKER & HOSTETLER LLP,
`is located at
`
` CIRA CENTRE, 12TH FLOOR
` 2929 ARCH STREET
` PHILADELPHIA, Pennsylvania 19104-2891
` US
`The docket/reference number is 099927.00038.
`
`The phone number is 215.568.3100.
`
`The fax number is 215.568.3439.
`
`The email address is BHIPDocket@bakerlaw.com; jlesser@bakerlaw.com; jmbarr@bakerlaw.com
`
`The applicants proposed correspondence information: Jacqueline M. Lesser. Jacqueline M. Lesser of BAKER & HOSTETLER LLP, is located at
` CIRA CENTRE, 12TH FLOOR
` 2929 ARCH STREET
` PHILADELPHIA, Pennsylvania 19104-2891
` United States
`The docket/reference number is 099927.00038.
`
`The phone number is 215.568.3100.
`
`The fax number is 215.568.3439.
`
`The email address is BHIPDocket@bakerlaw.com; jlesser@bakelaw.com; jmbarr@bakerlaw.com
`
`ADDITIONAL STATEMENTS
`Miscellaneous Statement
`The following is in response to the Office Action issued June 14, 2019. In accordance with the Trademark Examining Attorney's requirements,
`Applicant has attached as Exhibit A catalog and insert pages that support its use of its ATHENEX LOGO mark as a house mark. It is respectfully
`requested that the application proceed to publication.
`
`Original PDF file:
`mis-3898219243-20191212144107485440_._EXHIBIT_A_-.pdf
`Converted PDF file(s) ( 86 pages)
`Miscellaneous File1
`Miscellaneous File2
`Miscellaneous File3
`Miscellaneous File4
`Miscellaneous File5
`Miscellaneous File6
`Miscellaneous File7
`Miscellaneous File8
`Miscellaneous File9
`Miscellaneous File10
`Miscellaneous File11
`Miscellaneous File12
`Miscellaneous File13
`Miscellaneous File14
`Miscellaneous File15
`Miscellaneous File16
`Miscellaneous File17
`Miscellaneous File18
`Miscellaneous File19
`Miscellaneous File20
`Miscellaneous File21
`Miscellaneous File22
`Miscellaneous File23
`
`
`
`Miscellaneous File24
`Miscellaneous File25
`Miscellaneous File26
`Miscellaneous File27
`Miscellaneous File28
`Miscellaneous File29
`Miscellaneous File30
`Miscellaneous File3l
`Miscellaneous File32
`Miscellaneous File33
`Miscellaneous File34
`Miscellaneous File35
`Miscellaneous File36
`Miscellaneous File37
`Miscellaneous File38
`Miscellaneous File39
`Miscellaneous File40
`Miscellaneous File4l
`Miscellaneous File42
`Miscellaneous File43
`Miscellaneous File44
`Miscellaneous File45
`Miscellaneous File46
`Miscellaneous File47
`Miscellaneous File48
`Miscellaneous File49
`Miscellaneous File50
`Miscellaneous File51
`Miscellaneous File52
`Miscellaneous File53
`Miscellaneous File54
`Miscellaneous File55
`Miscellaneous File56
`Miscellaneous File57
`Miscellaneous File58
`Miscellaneous File59
`Miscellaneous File60
`Miscellaneous File6l
`Miscellaneous File62
`Miscellaneous File63
`Miscellaneous File64
`Miscellaneous File65
`Miscellaneous File66
`Miscellaneous File67
`Miscellaneous File68
`Miscellaneous File69
`Miscellaneous File70
`Miscellaneous File7l
`Miscellaneous File72
`Miscellaneous File73
`Miscellaneous File74
`Miscellaneous File75
`Miscellaneous File76
`Miscellaneous File77
`Miscellaneous File78
`Miscellaneous File79
`Miscellaneous File80
`Miscellaneous File81
`
`
`
`Miscellaneous File24
`Miscellaneous File25
`Miscellaneous File26
`Miscellaneous File27
`Miscellaneous File28
`Miscellaneous File29
`Miscellaneous File30
`Miscellaneous File31
`Miscellaneous File32
`Miscellaneous File33
`Miscellaneous File34
`Miscellaneous File35
`Miscellaneous File36
`Miscellaneous File37
`Miscellaneous File38
`Miscellaneous File39
`Miscellaneous File40
`Miscellaneous File41
`Miscellaneous File42
`Miscellaneous File43
`Miscellaneous File44
`Miscellaneous File45
`Miscellaneous File46
`Miscellaneous File47
`Miscellaneous File48
`Miscellaneous File49
`Miscellaneous File50
`Miscellaneous File51
`Miscellaneous File52
`Miscellaneous File53
`Miscellaneous File54
`Miscellaneous File55
`Miscellaneous File56
`Miscellaneous File57
`Miscellaneous File58
`Miscellaneous File59
`Miscellaneous File60
`Miscellaneous File61
`Miscellaneous File62
`Miscellaneous File63
`Miscellaneous File64
`Miscellaneous File65
`Miscellaneous File66
`Miscellaneous File67
`Miscellaneous File68
`Miscellaneous File69
`Miscellaneous File70
`Miscellaneous File71
`Miscellaneous File72
`Miscellaneous File73
`Miscellaneous File74
`Miscellaneous File75
`Miscellaneous File76
`Miscellaneous File77
`Miscellaneous File78
`Miscellaneous File79
`Miscellaneous File80
`Miscellaneous File81
`
`
`
`Miscellaneous File82
`Miscellaneous File83
`Miscellaneous File84
`Miscellaneous File85
`Miscellaneous File86
`
`SIGNATURE(S)
`Request for Reconsideration Signature
`Signature: /Jacqueline M. Lesser/ Date: 12/13/2019
`Signatory's Name: Jacqueline M. Lesser
`Signatory's Position: Attorney of record, PA bar member
`
`Signatory's Phone Number: 215.564.2155
`
`The signatory has confirmed that he/she is a U.S.-licensed attorney who is an active member in good standing of the bar of the highest court of a
`U.S. state (including the District of Columbia and any U.S. Commonwealth or territory); and he/she is currently the owner's/holder's attorney or
`an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S.-licensed attorney not currently associated
`with his/her company/firm previously represented the owner/holder in this matter: the owner/holder has revoked their power of attorney by a
`signed revocation or substitute power of attorney with the USPTO; the USPTO has granted that attorney's withdrawal request; the owner/holder
`has filed a power of attorney appointing him/her in this matter; or the owner's/holder's appointed U.S.-licensed attorney has filed a power of
`attorney appointing him/her as an associate attorney in this matter.
`
`The applicant is not filing a Notice of Appeal in conjunction with this Request for Reconsideration.
`
`Mailing Address: JACQUELINE M. LESSER
` BAKER & HOSTETLER LLP
` CIRA CENTRE, 12TH FLOOR
` 2929 ARCH STREET
` PHILADELPHIA, Pennsylvania 19104-2891
`Mailing Address: Jacqueline M. Lesser
` BAKER & HOSTETLER LLP
` CIRA CENTRE, 12TH FLOOR
` 2929 ARCH STREET
` PHILADELPHIA, Pennsylvania 19104-2891
`
`Serial Number: 87348251
`Internet Transmission Date: Fri Dec 13 15:07:47 EST 2019
`TEAS Stamp: USPTO/RFR-XX.XX.XXX.XXX-2019121315074781
`1173-87348251-70045e6d2a792d9fd29985412d
`c50cc5f03c3f10191820ae3b2571113b63cc1-N/
`A-N/A-20191212144107485440
`
`
`
`
`
`EXHIBIT A
`
`
`
`Ampicillin
`for Injection, USP
`
`250 mg per vial
`
`500 mg pervial
`
`1 gram pervial
`
`2 grams per vial
`
`10 grams per vial
`
`|
`
`|
`
`|
`
`|
`
`l
`
`NDC 70860-11245
`
`NDC 70860—ll3—15
`
`NDC 70860—ll4—15
`
`NDC 70860-l15-26
`
`NDC 70860—118—99
`
`ATHENEX AccuraSEESM PACKAGING AND LABELING
`
`BIG, BOLD AND BRIGHT —
`TO HELP YOU SEE IT, SAY IT AND PICK IT RIGHT
`
`DIFFERENTIATION IN EVERY LABEL,
`DESIGNED TO HELP REDUCE MEDICATION ERRORS
`
`1|
`l;
`‘5 "magmmiul:
`
`1mmummimun
`
`THE NEXT GENERATION OF PHARMACY INNOVATION
`
`
`
`
`
`.IJIIIIIIIIJJ"I"-
`
`v
`
`IIIIIl
`
`
`
`To order, call 1-855-273-0154 or visit www.Athenexpharma.com
`
`for Injection, USP
`
`Ampicillin
`NDC 70860-11245
`
`NDC msmmg
`250 mg per vial
`1 gram per vial
`Zagram per v‘ial
`DESCRIPTION
`GlassVial
`DESCRIPTION
`Glass Vial
`DESCRIPTION
`Class Vial
`DESCRIPTION
`Glass Vial
`
`
`NDC 70860-114-15
`
`
`CONCENTRATION
`250 mg per Vial
`CONCENTRATION
`500 mg per Vial
`CONCENTRATION
`I gram per Vial
`CONCENTRATION
`2 grams per Vial
`CLOSURE
`20 mm
`CLOSURE
`20 mm
`CLOSURE
`20 mm
`CLOSURE
`20 mm
`
`
`UNITOF SALE
`10 vials
`UNIT OF SALE
`10vials
`UNITOF SALE
`IOVials
`UNITOF SALE
`IOvials
`
`
`
`
`
`
`
`
`Yes BAR CODED Yes BAR CODED Yes BAR CODEDBAR CODED Yes
`
`NDC 70860-11899
`
`10 grams per vial
`Pharmacy Bulk
`Package
`10 grams per VIal
`32 mm
`
`DESCRIPTION
`CONCENTRATION
`CLOSURE
`
`UNIT OF SALE
`
`BAR CODED
`
`1 bottle
`
`Yes
`
`CHOOSE AccuraSEESM FOR YOUR PHARMACY
`
`PACKAGING & LABELINGr Our proprietary, differentiated
`
`and highly-visible label designs
`can assist pharmacists in
`accurate medication selection.
`
`ccuraSEE”
`
`With a unique label design for every Athenex product, we're ofierlng
`pharmacists added AccuraSEE for your pharmacy— and toryour
`patients' safety, The idea Is simple: ”So what you see is exactly what
`you get."
`
`Athenex,AccuraSEE and all label des gns are ccpyright afAthenex.
`@201 9 Athenex. APD7003170374/19
`
`
`
`thenex
`
`
`
`Azithromycin
`
`for Injection, USP
`
`500 mg pervial
`
`| NDC 70860—IOO—IO
`
`ATHENEX AccuraSEESM PACKAGING AND LABELING
`
`BIG, BOLD AND BRIGHT —
`TO HELP YOU SEE IT, SAY IT AND PICK IT RIGHT
`
`DIFFERENTIATION IN EVERY LABEL,
`DESIGNED TO HELP REDUCE MEDICATION ERRORS
`
`Single-Dose \fia
`
`INFUSION ONLY
`
`THE NEXT GENERATION OF PHARMACY INNOVATION
`
`
`
`Azithromycin
`
`for Injection, USP
`
`To order, call 1-855-273-0154 or visit www.Athenexpharma.com
`
`NDC 70860-100-10
`
`500 mg per vial
`
`Yes
`
`Class Vial
`
`500 mg per vial
`
`20 mm
`
`10 vials
`
`.
`.
`lmhmmymn
`‘Illgtninu us!
`
`>
`
`DESCRIPTION
`
`CONCENTRATION
`
`CLOSURE
`
`UNIT OFSALE
`
`BAR CODED
`
`CHOOSE AccuraSEESM FOR YOUR PHARMACY
`
`
`
`
`
`
`Our proprietarydifferentiated and highlyevisible IabeI designs
`CcuraSEE C3” aSSISt Pharmacists in accurate medication seiection.
`PACKAGING 3. LABELING
`With a unique AccuraSEE label design for every Athenex
`product, we’re helping your pharmacyto reduce the risk
`of medication errors.The idea is simple:“So what you see
`
`is exactly wh at you get."
`
`
`
`
`
`Athenex,AccuraSEEand all label deSignsarecopyright afAtheriex.
`©2019 Athenex. APDvOOO3v04v08/19
`
`thenex
`
`
`
`Busulfan
`Injection
`
`60 mg perIO mL | NDC 70860—216—IO
`
`. ATHENEXAccuraSEESM PACKAGING AND LABELING
`
`BIG, BOLD AND BRIGHT —
`TO HELP YOU SEE IT, SAY IT AND PICK IT RIGHT
`
`DIFFERENTIATION IN EVERY LABEL,
`DESIGNED TO HELP REDUCE MEDICATION ERRORS
`
`
`
`For Intravenous Infusion Only
`Caution: Must Be Diluted
`BeIore Use
`
`I
`
`
`
`1::mLSinalu-Du-n\llal
`
`.
`
`THE NEXT GENERATION OF PHARMACY INNOVATION
`
`
`
`Busulfan
`
`Injection
`
`To order, call 1-855-273-0154 or visit www.Athenexpharma.com
`
`NDC 70860-21640
`
`60 mg per 10 mL DESCRIPTION
`
`Class Vial
`
`6 mg per mL
`
`CONCENTRATION
`CLOSURE
`
`UNIT OFSALE
`
`BAR CODED
`
`20 mm
`
`8Vials
`
`Yes
`
`CHOOSE AccuraSEESM FOR YOUR PHARMACY
`
`
`
`
`
`
`Our proprietarydifferentiated and highlyevisible label designs
`CcuraSEE C3” 355“ Pharmacists in accurate medication selection.
`PACKAGING & LABELING
`With a unique AccuraSEE label design for every Athenex
`product, we’re helping your pharmacyto reduce the risk
`of medication errors.The idea is simple:“So what you see
`
`is exactly wh at you get."
`
`
`
`
`
`Athenex,AccuraSEEand all label desrgnsarecopyright afAthenex.
`©2019 Athenex. APD70056~01703N9
`
`thenex
`
`
`
`
`
`
`
`BUSULFAN Injection
`INDICATION AND USAGE
`- Busulfan injection is indicated for use in combination with
`cycloplrosphamide as a conditioning regimen prior to
`allogeneic hematopoietic progenitor cell transplantation
`forchronic myelogenous leukemia.
`IMPORTANT SAFETY IN FORMATION
`WARNING: MVELOSUPPRESSION
`BUSULFAN INJECTION CAUSES SEVERE AND PROLONGED
`MYELOSUPPRESSION ATTHE RECOMMENDED DOSAGE.
`HEMATOPOIETIC PROGENITOR CELLTRANSPLANTATION IS
`REQUIRED TO PREVENT POTENTIALLY FATAL COMPLICATIONS
`OF THE PROLONGED MYE LOSUPFRESSION
`CONTRAINDICATIONS
`- Busulfan is contraindicated In patrentswrth a
`history of hypersensitivity to any of its components.
`WARNINGS and PRECAUTIONS
`- Myelosuppression: The most frequent serious
`consequence oftreatment with busulfan at the
`recommended dose and schedule is prolonged
`myelosuppreSSion,occurring in all patients (100%).
`Severe granulocytopenia,thrombocytopenia, anemia,
`or any combination thereof may develop. IIematopoietic
`progenitor cell transplantation is required to prevent
`potentially fatal complications. Monitor complete
`blood counts, including white blood cell differentials,
`and quantitative platelet counts daily during treatment.
`Use antibiotic therapy and platelet and red blood cell
`support when medically indicated.
`- Seizures: Seizures have been reported in patients receiving
`highrdose oral busulfan at doses producing plasma drug
`levels srmilartothose achieved followrng the recommended
`dosage ofBusulfan Injection. Initiate phenytoin thera pyor
`any other alternative antieconvulsa nt prophylactictherapy
`(e g,benzodiazepines,valproic acid or levetiracetam) priorto
`busulfan Injection treatment. Use caution when administering
`the recommended dose ofBusulfan Injection to patients
`with a history of a seizure disorder or head trauma or who
`are receiving other potentiallyep
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
